


. . .

## ent Application for: Sustained Release Formulations Inventor(s): Franklin Okumu Attorney Docket No.: 10466/18 Page 2 of 9







Figure 3. The effect solvent on the release of rhGH from SABER formulations








Figure 4. The effect protein formulation has on the release of rhGH from SABER formulations

SAIB:Solvent	Growth Hormone Formulation	% Release over 24 hours	% Daily Release 0-21 days
Ethanol (85:15)	Zinc	0.53	0.10
Ethanol (85:15)	Bicarbonate	6.53	0.73
Benzyl Benzoate (70		1.06	0.73
Benzyl Benzoate (70	:30) Bicarbonate	14.64	2.16








Figure 6. Effect of solvent quality on stability of rhGH released from SABER formulations containing reagent and USP grade benzyl benzoale

Reagent grade

UPS grade




Figure 7. The effect a chelating agent (EDTA) has on the release of zinc complexed rhGH from SABER formulations

ETHANGLISTO) Benzyl tengate



FDTA + E.DTA -






Figure 8. The effect buffer exposed surface area and SABER:buffer ratio have on the release rhGH from SABER formulations

Patent Application for: Sustained Release Formulations Inventor(s): Franklin Okumu Attorney Docket No.: 10466/18 Page 9 of 9

PLGA microspheres
 Benzyl benzoate (30%)
 ▲ Benzyl alcohof (30%)




Figure 9. rhGH serum levels after SC administration of rhGH SABER formulations (SD rats, 6/group, 15 mg/Kg)